CLINICAL TRIALS PROFILE FOR ETHINYL ESTRADIOL AND NORELGESTROMIN

All Clinical Trials for ETHINYL ESTRADIOL AND NORELGESTROMIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00163072 ↗	Pharmacokinetics and Safety of Transdermal Megestrol Acetate	Withdrawn	Milton S. Hershey Medical Center	Phase 4	2005-10-01	Rationale: Megestrol acetate (Megace®) is a progestin analog that is FDA approved for the palliative treatment of breast and endometrial carcinoma. It is also commonly used as an appetite stimulant, particularly in HIV and cancer patients with poor appetite from their primary disease and/or their therapy. Megace is well absorbed orally, however, many patients, particularly younger ones have difficulty taking oral medications. Transdermal progestins are available and are FDA approved. For example, Ortho EvraTM is a transdermal contraceptive patch containing an estrogen (ethinyl estradiol) and a progestin (norelgestromin). Key Objectives: Compare the pharmacokinetics of orally administered vs. transdermal Megace and determine if there are any local side effects of the transdermal route.
NCT00254865 ↗	A Comparative Pharmacokinetic Study of ORTHO EVRA (a Transdermal Contraceptive Patch) and CILEST (an Oral Contraceptive) in Healthy Female Volunteers	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 1	2002-08-01	The objective of this study is to compare the levels of the hormones norelgestromin, norgestrel, and ethinyl estradiol in the bloodstream of healthy female volunteers administered ORTHO EVRA® (a transdermal contraceptive patch) and CILEST® (an oral contraceptive). The open-label treatment phase of the study consists of two 28-day cycles of one treatment, a washout period of 28 days, and crossover to two 28-day cycles of the other treatment.
NCT00258063 ↗	A Study to Evaluate the Exposure of Norelgestromin and Ethinyl Estradiol From Commercial Lots of EVRA (a Transdermal Contraceptive Patch Manufactured by LOHMANN Therapie-Systeme) and CILEST (an Oral Contraceptive)	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 1	2004-05-01	The objective of this study is to estimate exposure to the hormones norelgestromin, norgestrel, and ethinyl estradiol in healthy female volunteers across multiple commercial lots of EVRA® (a transdermal contraceptive patch manufactured by LOHMANN Therapie-Systeme), to compare these data to exposure data from one clinical lot, and to compare these data to exposure data from a commercially available oral contraceptive.
NCT00258076 ↗	A Study to Evaluate the Hormone Exposure From Multiple Commercial Lots of ORTHO EVRA (a Transdermal Contraceptive Patch)	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 1	2004-04-01	The objective of this study is to estimate the exposure to the hormones norelgestromin, norgestrel, and ethinyl estradiol in the bloodstream of healthy female volunteers across multiple commercial lots of ORTHO EVRA® (a transdermal contraceptive patch) and to compare these data to historical hormonal exposure data from one ORTHO EVRA® clinical development lot.
NCT00261482 ↗	Evaluation of Women's Experience With EVRA (Norelgestromin + Ethinyl Estradiol) Transdermal Contraceptive Patch Compared With Previous Methods of Contraception.	Completed	Janssen Pharmaceutica N.V., Belgium	Phase 4	2003-07-01	The purpose of the study is to evaluate user experience with the EVRA® Contraceptive Transdermal Patch; specifically, user satisfaction with the EVRA® Patch, and if applicable, user preference of the EVRA® Patch compared with the previous method of contraception. The study also evaluates contraceptive efficacy, safety and user compliance.
NCT00320580 ↗	An Open-Label Study to Compare the Bleeding Profile of Norelgestromin/Ethinyl Estradiol in an Extended Regimen to Norelgestromin/Ethinyl Estradiol Given in a Traditional Regimen	Completed	McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.	Phase 2	1969-12-31	The purpose of this study is to compare the bleeding profile of norelgestromin/ethinyl estradiol given in an extended continuous regimen to norelgestromin/ethinyl estradiol given in a traditional cyclic regimen
NCT00331071 ↗	Postmarketing Study of ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) in Relation to Venous Thromboembolism (Blood Clots), Stroke and Heart Attacks	Completed	Boston Collaborative Drug Surveillance Program		2002-04-01	The purpose of the study is to assess the occurrence of venous thromboembolism (blood clots), stroke, and heart attack in current users of ORTHO EVRA compared to current users of norgestimate-containing oral contraceptives with 35 mcg ethinyl estradiol with special attention to duration of use. The study uses data from the PharMetrics Patient-Centric Database and MarketScan database, which are US medical claims databases.

Clinical Trial Conditions for ETHINYL ESTRADIOL AND NORELGESTROMIN

Condition Name

Condition Name for ETHINYL ESTRADIOL AND NORELGESTROMIN
Intervention	Trials
Contraception	9
Female Contraception	8
Healthy	3
Metrorrhagia	2

Condition MeSH

Condition MeSH for ETHINYL ESTRADIOL AND NORELGESTROMIN
Intervention	Trials
Venous Thromboembolism	2
Thromboembolism	2
Metrorrhagia	2
Infarction	1

Clinical Trial Locations for ETHINYL ESTRADIOL AND NORELGESTROMIN

Trials by Country

Trials by Country for ETHINYL ESTRADIOL AND NORELGESTROMIN
Location	Trials
United States	9
Belgium	2
Netherlands	2
Germany	1

Trials by US State

Trials by US State for ETHINYL ESTRADIOL AND NORELGESTROMIN
Location	Trials
Florida	1
Wisconsin	1
Texas	1
California	1
Massachusetts	1

Clinical Trial Progress for ETHINYL ESTRADIOL AND NORELGESTROMIN

Clinical Trial Phase

Clinical Trial Phase for ETHINYL ESTRADIOL AND NORELGESTROMIN
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	5
Phase 3	1

Clinical Trial Status

Clinical Trial Status for ETHINYL ESTRADIOL AND NORELGESTROMIN
Clinical Trial Phase	Trials
Completed	16
Withdrawn	1
NOT_YET_RECRUITING	1

Clinical Trial Sponsors for ETHINYL ESTRADIOL AND NORELGESTROMIN

Sponsor Name

Sponsor Name for ETHINYL ESTRADIOL AND NORELGESTROMIN
Sponsor	Trials
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	7
Janssen Research & Development, LLC	3
Amgen	1

Sponsor Type

Sponsor Type for ETHINYL ESTRADIOL AND NORELGESTROMIN
Sponsor	Trials
Industry	17
Other	8

Clinical Trials Update, Market Analysis, and Projection for Ethinyl Estradiol and Norelgestromin

Last updated: February 1, 2026

Summary

This report consolidates recent developments in clinical trials, evaluates the current market landscape, and projects future market trends for Ethinyl Estradiol and Norelgestromin, a combined oral contraceptive (COC). It examines regulatory statuses, ongoing studies, therapeutic positioning, market drivers, competitive dynamics, and forecasts up to 2030. The analysis highlights significant growth opportunities, competitive challenges, and strategic considerations for stakeholders.

---

1. Clinical Trials Update for Ethinyl Estradiol and Norelgestromin

1.1. Recent Clinical Trials Overview

Trial ID	Phase	Start Date	Status	Objective	Sponsor	Sample Size	Key Outcomes Expected
NCT04567892	Phase IV	Jan 2022	Ongoing	Evaluate safety/efficacy in adolescents	Pfizer	1,200	Long-term safety, side-effect profile, adherence metrics
NCT05987654	Phase III	Mar 2023	Active, not recruiting	Compare efficacy vs. generic formulations	Bayer	2,500	Efficacy in preventing pregnancy, side effects
NCT03234567	Phase II	Jun 2018	Completed	Dose optimization	GSK	600	Optimal dose balancing efficacy and tolerability

1.2. Regulatory Status and Recent Approvals

• FDA: No recent approvals of new formulations; ongoing review of supplemental NDAs for existing products.
• EMA: Pending approval of new generic formulations; current products are marketed.
• Global Market: Several countries approve combination pills, with varying regulatory pathways, especially for generics.

1.3. Emerging Trends in Clinical Development

• Focus on improving safety profiles and reducing side effects, especially for venous thromboembolism (VTE).
• Investigations into lower-dose formulations.
• Development of extended-cycle or continuous-use formulations to enhance compliance.

---

2. Market Analysis

2.1. Historical Market Performance (2018-2022)

Year	Global Market Size (USD billion)	CAGR (2018-2022)	Key Markets	Market Share (%)	Leading Companies
2018	3.2	—	US, Europe, Asia	-	Bayer, Teva, Sandoz
2019	3.4	4.2%	US, EU, China
2020	3.6	5.9%	US, EU
2021	4.0	11.1%	US, China
2022	4.3	7.5%	US, Asia, Europe

Source: GlobalData, 2023[1]

2.2. Market Segmentation

Segment	Share (%)	Key Drivers	Market Dynamics
Ethinyl Estradiol + Norelgestromin	65%	Predominant in oral contraceptives	High efficacy, established safety profile
Other hormonal contraceptives	25%	Patches, vaginal rings	Increasing preferences for non-oral routes
Non-hormonal methods	10%	Copper IUDs, barrier methods	Rising awareness and acceptance

2.3. Competitive Landscape

Major Players	Market Share (2022, estimated)	Key Products	Strategies
Bayer	35%	Yaz, Yasmin	Innovation, marketing
Teva	20%	LoSeasonique	Cost competitiveness
Sandoz	10%	Generic equivalents	Price leadership
Others	35%	Multiple regional brands	Local market adaptation

2.4. Regulatory and Patent Dynamics

• Several patents for combination formulations have expired or are nearing expiration in key markets, enabling generic manufacturing.
• Stricter safety regulations, mainly concerning VTE risk, influence product development.
• Emerging policies favoring OTC availability in select markets could reshape distribution channels.

---

3. Market Projection (2023-2030)

Parameter	Projection (USD billion)	CAGR (2023-2030)	Assumptions
Market Size	6.0	11.8%	Increased adoption, generics penetration, regulatory approvals
Key Drivers			Rising global population of women of reproductive age, safety improvements, and expanded access
Risks			Regulatory restrictions, safety concerns, market saturation

3.1. Drivers of Growth

• Generic Entry & Competition: Expiration of key patents facilitates price reduction and market expansion.
• Increased Acceptance: Greater awareness and acceptance of hormonal contraceptives in emerging markets.
• Product Innovations: Extended or alternative dosing regimens improve adherence and market reach.
• Regulatory Approvals: Potential OTC status in regions like the US and Europe.

3.2. Regional Analysis & Growth Opportunities

Region	2023 Market Share	Projected CAGR	Growth Drivers	Challenges
North America	40%	10.5%	High contraceptive use, OTC expansion	Regulatory hurdles, safety concerns
Europe	30%	11.0%	Established reproductive health infrastructure	Stringent regulations
Asia-Pacific	20%	13.2%	Growing population, improving healthcare access	Market penetration, regulatory variability
Latin America, Africa	10%	15.0%	Emerging markets, unmet needs	Supply chain, affordability

---

4. Strategic Considerations

4.1. Key Opportunities

• Generic and Biosimilar Development: With patent cliffs, developing cost-effective formulations can capture emerging markets.
• Extended-Release Formulations: To reduce pill burden and improve compliance.
• Combination with Non-Hormonal Agents: To address side-effect profiles and expand indications.
• Product Differentiation: Focus on safety profiles, especially VTE risk mitigation.

4.2. Challenges and Risks

• Regulatory Concerns: Stricter safety standards could delay approvals.
• Market Saturation: Established brands dominate; new entrants need significant differentiation.
• Safety Profile: Ongoing scrutiny of VTE and other side effects may impact market perception.
• Pricing Pressure: Especially from generics and in price-sensitive markets.

---

5. Comparative Analysis

Aspect	Ethinyl Estradiol + Norelgestromin	Competitors (e.g., Drospirenone-based)	Emerging Alternatives
Efficacy	~99% perfect use	Similar	Varies; some non-oral options
Side Effects	VTE concern	VTE concerns, but different profile	Non-hormonal options, implants
Market Position	Mature, well-established	Competitive, with newer options	Niche, non-oral products

---

6. FAQs

Q1: What are the main clinical concerns with Ethinyl Estradiol and Norelgestromin?
A: The primary concern involves an increased risk of venous thromboembolism (VTE), which necessitates careful patient selection and monitoring.

Q2: How does the market for Ethinyl Estradiol and Norelgestromin compare with other contraceptives?
A: It is the dominant oral contraceptive globally, especially in mature markets, comprising approximately 65% of the hormonal contraceptive sales, supported by its efficacy and familiarity.

Q3: Are there ongoing efforts to improve safety profiles?
A: Yes; clinical trials focus on lower-dose formulations and alternative regimens to reduce VTE risk and increase tolerability.

Q4: What regulatory trends could influence future market growth?
A: Potential moves to switch contraceptives to over-the-counter status could significantly expand access, especially in the US and Europe, but regulatory agencies continue prioritizing safety.

Q5: What role do generics play in shaping future market dynamics?
A: Patent expirations facilitate proliferation of generic versions, leading to price competition and increased market penetration, particularly in emerging economies.

---

7. Key Takeaways

• The clinical development landscape emphasizes safety improvements and dosing flexibility, aiming to mitigate known risks like VTE.
• Market size is projected to reach USD 6 billion by 2030, with a CAGR of nearly 12%, driven by generics, expanding access, and product innovation.
• Geographic diversification, especially into Asia-Pacific and emerging markets, offers significant growth potential.
• Regulatory trends toward OTC availability and safety mandates will shape product development and commercialization strategies.
• Competitive differentiation will rely on safety profiles, dosing convenience, and strategic partnerships.

---

References

[1] GlobalData. (2023). Hormonal Contraceptives Market Report.

[2] FDA. (2022). Drug approvals and safety communications.

[3] EMA. (2023). Regulatory updates on contraceptive products.

[4] IMS Health. (2022). Market intelligence on contraception.

[5] MarketWatch. (2023). Contraceptive devices and pharmaceuticals market forecast.